Ten years ago, Detroit was still recovering from the 2007/2008 Great Recession in which hundreds of thousands of people lost their jobs and Detroit’s biggest industry, the auto industry, was struggling.
Relmada Therapeutics Inc (NASDAQ: RLMD) announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3 trial (Study 310) of REL-1017 in patients with